KEITA MORI

Regenerative medicine is transforming the way healthcare addresses complex diseases and injuries by focusing on repairing damaged tissues instead of simply managing symptoms. Among the companies driving this progress is SanBio Co., Ltd., a Tokyo-based biotechnology company dedicated to developing regenerative cell medicines for patients with neurological disorders. With a strong scientific foundation, an expanding clinical pipeline, and a commitment to improving patients’ quality of life, SanBio has established itself as an innovator in the regenerative medicine sector. 

Founded in 2001 and headquartered in Tokyo, SanBio focuses on the research, development, manufacturing, and commercialization of regenerative cell medicines. The company combines Japanese scientific excellence with international expertise through its U.S. subsidiary, SanBio, Inc., enabling it to conduct research and clinical development on a global scale. Its mission centers on bringing regenerative medicine closer to patients by creating therapies that address conditions with limited treatment options. 

A Mission to Restore Lost Function

SanBio believes regenerative medicine has the potential to change the future of healthcare by helping the body repair itself. Rather than treating only the symptoms of neurological conditions, the company’s approach aims to restore lost functions by supporting the brain’s natural healing mechanisms.

Its long-term vision is to make regenerative medicine accessible to patients worldwide through continuous innovation, scientific collaboration, and responsible product development. This patient-centered philosophy guides every stage of its research and clinical programs. 

SB623: A Flagship Regenerative Cell Therapy

At the center of SanBio’s research portfolio is SB623, an allogeneic regenerative cell therapy derived from modified mesenchymal stem cells obtained from healthy adult bone marrow. Unlike traditional stem cell therapies that primarily replace damaged cells, SB623 is designed to stimulate the body’s own repair mechanisms by promoting tissue regeneration and improving the environment around injured brain tissue. 

The therapy has been studied for patients suffering from chronic neurological deficits, particularly those caused by traumatic brain injury (TBI) and stroke. These conditions often leave patients with long-term motor impairments and limited treatment options once the acute phase has passed.

SanBio has invested years of research into demonstrating the potential of SB623, conducting multiple clinical studies in Japan and the United States to evaluate its safety and therapeutic effectiveness. The company’s work represents one of the most advanced regenerative medicine programs targeting chronic neurological disorders. 

Building a Strong Regenerative Medicine Platform

SanBio’s competitive strength extends beyond a single therapy. The company has developed an integrated regenerative medicine platform that combines advanced cell processing technologies, scalable manufacturing capabilities, and specialized expertise in neurological disease research.

Its research and development strategy focuses on several important areas:

• Advanced regenerative cell technologies
• Efficient large-scale manufacturing processes
• High-quality product consistency
• Strong intellectual property protection
• Clinical development for neurological diseases

This comprehensive approach allows SanBio to move promising therapies from laboratory research through clinical development while preparing for future commercialization. 

Expanding Clinical Development

SanBio continues to strengthen its clinical development efforts by evaluating regenerative therapies for conditions where existing treatment options remain limited. The company’s clinical research programs emphasize rigorous scientific evaluation while working closely with regulatory authorities and healthcare institutions.

Its development pipeline reflects a long-term commitment to regenerative medicine and highlights opportunities to apply its technology platform across multiple neurological indications. By maintaining a focused pipeline, SanBio seeks to maximize both scientific impact and patient benefit. 

Strategic Partnerships for Global Growth

Collaboration plays an important role in SanBio’s growth strategy. The company works with academic researchers, medical institutions, and industry partners to accelerate innovation and expand the reach of regenerative medicine.

These partnerships support clinical research, manufacturing development, and future commercialization efforts while enabling SanBio to access specialized expertise across different regions and therapeutic areas. International collaboration also strengthens the company’s ability to develop therapies for patients worldwide. 

Leadership Driving Scientific Innovation

SanBio’s strategic direction is led by Keita Mori, President and Representative Director of SanBio Co., Ltd. and CEO of SanBio, Inc. His career combines scientific research, manufacturing experience, product development, and business leadership.

After beginning his career at Kirin Brewery Company in production management and research and development, Mori gained experience leading new product development at an informatics company in California’s San Francisco Bay Area before founding SanBio, Inc. His educational background includes degrees in Agricultural Chemistry from the University of Tokyo and an MBA from the University of California, Berkeley. His multidisciplinary expertise has helped shape SanBio’s vision of translating advanced science into practical regenerative therapies. 

Looking Ahead

As regenerative medicine continues to evolve, SanBio remains focused on delivering innovative therapies that address significant unmet medical needs. Its investments in cell therapy research, clinical development, manufacturing technologies, and strategic partnerships position the company to contribute meaningfully to the future of neurological care.

With its flagship SB623 program, a dedicated scientific team, and a mission centered on improving patients’ lives, SanBio continues to advance regenerative medicine toward practical clinical applications. By combining scientific innovation with patient-focused development, the company is helping shape a future where regenerative therapies become an increasingly important part of modern healthcare.